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OBJECTIVES: To identify factors affecting cost-effectiveness threshold calculation in 
Korea. METHODS: As a pilot study of the Korean cost-effectiveness threshold study, 
a survey questionnaire using EQ-5D to measure QALY improvements and WTPs in 
hypothetical scenarios were developed. 219 Koreans from general population were 
interviewed face-to-face with this questionnaire in 2009. Each person’s WTPs were 
asked for ﬁve scenarios chosen from each level of Korean EQ-5D tariff (KCDC): 0∼0.2, 
0.2∼0.4, 0.4∼0.6, 0.6∼0.8, 0.8∼1.0. The same WTP questions were repeated for the 
QALY improvement of a family member instead of self. The questionnaire also 
included questions on demographics, disease status, and a visual analog scale (VAS) 
measure of each scenario presented. Consistency of each respondent was checked by 
matching ranks of ﬁve scenarios between WTPs and QALY improvements either by 
VAS or KCDC tariff. The distribution of WTP values can provide random starting 
values for a large-scale double-bounded dichotomous choices survey in 2010. 
RESULTS: The WTP for an additional QALY (calculated by VAS and three existing 
Korean EQ-5D tariffs) was around 10–25 million KRW (9164∼22927 USD, 1 USD 
= 1150 KRW) on average for those (N = 150) who passed consistency check and not 
under medical assistance program (zero or low copayment). The averages of WTP for 
a family member were 2.6–5.4 million KRW (2328∼4913 USD) higher than WTP for 
self. Respondents from Seoul (N = 112) showed signiﬁcantly higher WTP averages 
(5–12 million KRW higher, 4103–10787 USD higher; p < 0.05) than nonresidents of 
Seoul (N = 38). The relationship between WTP and QALY improvements measured 
by VAS was monotonic (people more appreciate signiﬁcant improvements) whereas 
the relationship between WTP and QALY improvements measured by Korean tariffs 
were highest at 0∼0.2 level. CONCLUSIONS: The choice of method to calculate 
QALY improvement seems crucial in cost-effectiveness threshold study in Korea. 
Other important factors include WTP for whom and living in Seoul.
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ECONOMIC MODELS: MANAGED CARE DECISION MAKER’S 
PERCEPTIONS AND USE
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OBJECTIVES: To 1) identify the types and characteristics of economic models plans 
are currently using; 2) identify concerns with these models; and 3) assess thoughts on 
the future importance of modeling. In 2000 the AMCP introduced its template for 
dossiers, which includes an economic model. Little is known about how payers use 
economic models, their perceived limitations, and how recent health care initiatives, 
such as comparative effectiveness research (CER), might impact use of economic 
models by health-plan decision-makers. METHODS: A web-based survey of 60 
managed care payers was conducted in September 2009 to assess perceptions and roles 
of economic models in decision-making. RESULTS: A total of 60 responses (35 
pharmacy directors, 17 medical directors, 4 consultants, and 4 others) representing 
more than 85 million lives, was received. 50% of respondents reported that they only 
used in-house models, 22% used both in-house and industry models, while 23% did 
not use economic models. Budget impact models were preferred by 23% of respon-
dents, cost-effectiveness models by 15%; 62% thought both were equally important. 
Microsoft Excel (65%) was the preferred software platform; AWP (25%) and WAC 
(27%) were the preferred drug pricing references. The majority believed that models 
should include the costs of treating AEs (50%) and off-label use (62%). Over half 
(55%) felt QALYs are not a trustworthy measure and a majority (75%) had little 
trust in industry sponsored models, largely due to a lack of credible inputs and data 
sources (37%). Most decision-makers (57%) believe that models will become more 
important over the next 2 to 3 years, and 72% believe that CER will increase the 
relevance of models. CONCLUSIONS: Results indicate that the majority of payers 
use economic models, believe that economic models will become more important in 
the near future, and think that CER will make models more relevant.
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OBJECTIVES: Health care stakeholders invest signiﬁcant resources into developing 
and disseminating comparative effectiveness information. One of the primary goals is 
to provide health care decision-makers with unbiased information on which to base 
their decisions. The study purpose was to determine the types of comparative effective-
ness information that would be most useful to formulary decision-makers. METHODS: 
In-depth interviews were conducted with formulary decision-makers in ten health 
plans. Between two to four interviews were conducted with each plan and included 
at least one medical director and one pharmacy director. Participants were provided 
with two published articles describing cost effectiveness models for secondary stroke 
prevention. Interviews then explored the following topics: what types of comparative 
effectiveness information are typically used for decision-making, which of the two 
models were most salient and the characteristics that made that model more useful, 
what types of comparative effectiveness information would be most useful in the 
future. RESULTS: Most, but not all, participants used some type of comparative 
effectiveness information in their decision making process. Including cost information 
in comparative effectiveness information was essential to them. The vast majority of 
the participants preferred a more simple methodological approach rather than models 
that use advanced statistical methods. Participants felt that the appropriate timeframe 
for models was approximately 1–3 years. The source of the information was important 
as participants wanted unbiased information and did not trust information provided 
by industry. Finally, most participants seemed to favor a single source for reliable cost 
effectiveness information. CONCLUSIONS: Comparative effectiveness researchers 
must be mindful of the needs of one of the primary audiences, health care decision-
makers, to ensure that the information is salient to them. Current approaches of the 
development of complex and advanced methods seem to be counter to what health 
care decision-makers want.
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A FURTHER STUDY ON PREFERRED DRUG BENEFIT PLANS FOR CIVIL 
SERVANT MEDICAL BENEFIT SCHEME IN THAILAND
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OBJECTIVES: To further examine preferred drug beneﬁt plan for civil servant medical 
beneﬁt scheme (CSMBS) in Thailand. METHODS: Two types of questionnaires modi-
ﬁed from previous studies were sent to 1,000 conveniently selected civil servants 
residing in two provinces. The questionnaire included ten hypothetical drug beneﬁt 
plans containing four attributes e.g. cost sharing, formulary, accessibility, and quan-
tity. Those two questionnaires contained different types of the cost sharing attribute, 
copayment and coinsurance. The respondents were asked to rate their satisfaction 
levels of each plan on Likert scale. Conjoint analysis was used to calculate utility 
weights and relative importance. RESULTS: Results from 293 questionnaires having 
copayment, as the cost sharing attribute, showed the beneﬁciaries weighed highest 
importance, 30.18%, on the formulary attribute. The beneﬁciaries preferred having 
access to drugs both listed and not listed in national essential drug list. The second 
important attribute was the cost sharing and its relative importance was 24.97%. The 
beneﬁciaries preferred lower level of copayment at 20 baht. The beneﬁciaries similarly 
weighed importance level on the attributes of accessibility and quantity at 22.47% 
and 22.38%, respectively. Results from 330 questionnaires having coinsurance, as the 
cost sharing attribute, showed the beneﬁciaries weighed highest importance, 33.23%, 
on the cost sharing. The beneﬁciaries preferred lower level of coinsurance at 10%. 
The second important attribute was the formulary restriction and its relative impor-
tance was 26.05%. The beneﬁciaries preferred having access to drugs both listed and 
not listed in national essential drug list. The beneﬁciaries similarly weighed importance 
level on the attributes of accessibility and quantity at 21.02% and 19.96%, respec-
tively. CONCLUSIONS: The CSMBS beneﬁciaries weighed on the cost sharing and 
formulary attributes to be more important than the accessibility and quantity attri-
butes when they considered drug beneﬁt plans.
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OBJECTIVES: This study sought to summarize effects of formulary controls on medi-
cation use and outcomes in the US elderly population in an effort to inform future 
Medicare Part D coverage decisions. METHODS: A systematic review was conducted 
identifying studies using search terms in PubMed, and Google Scholar. Journals per-
taining to health care issues in the elderly were reviewed. Search terms such as 
Medicare, copayment, compliance, outcomes, and utilization covered the following 
areas: 1) impact of formulary control on medication use (e.g. adherence, prescription 
ﬁlls) and 2) impact of medication use on health outcomes. Articles published prior to 
1995, that were not original empirical research, published in languages other than 
English, and studied populations other than US Medicare beneﬁciaries were excluded. 
Studies were categorized based on the statistical signiﬁcance of relationships deﬁned 
a priori. RESULTS: A total of 54 research articles were reviewed. The majority evalu-
ated the impact of drug coverage or cost share (copayment or coinsurance) on medica-
tion use. Impact of drug coverage was assessed by comparing patients with some drug 
coverage to those with no drug coverage or comparing patients with varying levels of 
drug coverage. Overall, 24 studies examined the impact of level of drug coverage on 
medication use; 96% showed that richer drug coverage or having some drug coverage 
signiﬁcantly improved medication use. Further, 19 studies examined the effect of cost 
share on medication use; 84% showed that decreased cost share signiﬁcantly improved 
medication use. Finally, 89% of studies (n = 9) showed that increased medication use 
was associated with signiﬁcantly improved economic and clinical outcomes. CON-
CLUSIONS: The preponderance of evidence existing in the literature to date suggests 
that restricting drug coverage or increasing out-of-pocket expenses for the elderly may 
lead to decreased medication utilization, potentially leading to poorer patient out-
comes and greater health care costs.
